Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 8, 2009 - Issue 3
Submit an article Journal homepage
257
Views
14
CrossRef citations to date
0
Altmetric
Reviews

Statins and the risk of Parkinson disease: an update on the controversy

Claudia Becker University Hospital Basel, Division of Clinical Pharmacology and Toxicology, Basel Pharmacoepidemiology Unit, Hebelstrasse 2, CH-4031 Basel, Switzerland
, PhD &
Christoph R Meier University Hospital Basel, Division of Clinical Pharmacology and Toxicology, Basel Pharmacoepidemiology Unit, Hebelstrasse 2, CH-4031 Basel, Switzerland; Boston University Medical Center, Boston Collaborative Drug Surveillance Program, Lexington, MA, USA +1 41 61 265 88 70; +1 41 61 265 45 60; [email protected]
, PhD MSc
Pages 261-271 | Published online: 15 Apr 2009

Bibliography

  • Galvan A, Wichmann T. Invited review: pathophysiology of parkinsonism. Clin Neurophysiol 2008;119:1459-74
  • Langston JW. The Parkinson's complex: parkinsonism is just the tip of the iceberg. Ann Neurol 2006;59:591-6
  • Schapira AH, Gu M, Taanman JW, et al. Mitochondria in the etiology and pathogenesis of Parkinson's disease. Ann Neurol 1998;44:S89-98
  • Hirsch EC, Hunot S, Hartmann A. Neuroinflammatory processes in Parkinson's disease. Parkinsonism Relat Disord 2005;11(Suppl 1):S9-15
  • Jenner P. Oxidative stress in Parkinson's disease. Ann Neurol 2003;53(Suppl 3):S26-36; discussion S36-38
  • Hardy J, Cai H, Cookson MR, et al. Genetics of Parkinson's disease and parkinsonsim. Ann Neurol 2006;60:389-98
  • Warner TT, Schapira AH. Genetic and environmental factors in the cause of Parkinson's disease. Ann Neurol 2003;53(Suppl 3):S16-23; discussion S23-5
  • Biskup S, Gerlach M, Kupsch A, et al. Genes associated with Parkinson syndrome. J Neurol 2008;255(Suppl 5):8-17
  • Mena MA, de Yebenes JG. Drug-induced parkinsonism. Exp Opin Drug Saf 2006;5:759-71
  • de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol 2006;5:525-35
  • de Rijk MC, Breteler MM, Graveland GA, et al. Prevalence of Parkinson's disease in the elderly: The Rotterdam Study. Neurology 1995;45:2143-6
  • Dorsey ER, Constantinescu R, Thompson JP, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007;68:384-6
  • National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421
  • Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National cholesterol education program adult treatment panel III guidelines. Circulation 2004;110:227-39
  • National Institute for Health and Clinical Excellence. CG67 Lipid modification: NICE guideline (issued 22 Sept 2008).Available from: http://www.nice.org.uk/nicemedia/pdf/CG67NICEGuideline.pdf. [Accessed at 31 Oct 2008]
  • Simes J, Furberg CD, Braunwald E, et al. Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling project. Eur Heart J 2002;23:207-15
  • Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58
  • Ford I, Murray H, Packard CJ, et al. Long-term follow-up of the West of Scotland Coronary Prevention Study. NEJM 2007;357:1477-86
  • Goldstein LB, Amarenco P, Lamonte M, et al. Relative effects of statin therapy on stroke and cardiovascular events in men and women: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study. Stroke 2008;39:2444-8
  • Shaw SM, Fildes JE, Yonan N, Williams SG. Pleiotropic effects and cholesterol-lowering therapy. Cardiology 2009;112:4-12
  • Wang CY, Liu PY, Liao JK. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med 2008;14:37-44
  • Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005;45:89-118
  • Jick SS, Choi H, Li L, et al. Hyperlipidemia, statin use and the risk of developing rheumatoid arthritis. Ann Rheum Dis 2008 In press
  • Okamoto H, Koizumi K, Kamitsuji S, et al. Beneficial action of statins in patients with rheumatoid arthritis in a large observational cohort. J Rheumatol 2007;34:964-8
  • Wekerle H. Tackling multiple sclerosis. Nature 2002;420:39-40
  • Vollmer T, Key L, Durkalski V, et al. Oral simvastatin treatment in relapsing-remitting multpile sclerosis. Lancet 2004;363:1607-8
  • Paul F, Waiczies S, Wuerfel J, et al. Oral high-dose atorvastatin treatment in relapsing-remitting multiple sclerosis. PLoS One 2007;3:e1928
  • Haag MD, Hofmann A, Koudstaal PJ, et al. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J Neurol Neurosurg Psychiatry 2008 In press
  • Li G, Larson EB, Sonnen JA, et al. Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease. Neurology 2007;69:878-85
  • Jick H, Zornberg GL, Jick SS, et al. Statins and the risk of dementia. Lancet 2000;356:1627-31
  • Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990;343:425-30
  • Laufs U, Endres M, Custodis F, et al. Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feedback regulation of Rho GTPase gene transcription. Circulation 2000;102:3104-10
  • Sundaresan M, Yu ZX, Ferrans VJ, et al. Regulation of reactive-oxygen-species generation in fibroblasts by Rac1. Biochem J 1996;318:379-82
  • Zipp F, Waiczies S, Aktas O, et al. Impact of HMG-CoA reductase inhibition on brain pathology. Trends Pharmacol Sci 2007;28:342-9
  • Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol 2004;19:117-25
  • Mason RP, Walter MF, Day CA, Jacob RF. Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions. Am J Cardiol 2005;96:11-23
  • Mason RP. Molecular basis of differences among statins and a comparison with antioxidant vitamins. Am J Cardiol 2006;98(Suppl):34P-41P
  • Hamelin BA, Turgeon J. Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci 1998;19:26-37
  • Hunot S, Hirsch EC. Neuroinflammatory processes in Parkinson's disease. Ann Neurol 2003;53(Suppl 3):S49-58; discussion S58-60
  • McGeer PL, McGeer EG. Inflammation and neurodegeneration in Parkinson's disease. Parkinsonism Relat Disord 2004;10(Suppl 1):S3-7
  • Whitton PS. Inflammation as a causative factor in the aetiology of Parkinson's disease. Br J Pharmacol 2007;150:963-76
  • Greenamyre JT, Hastings TG. Biomedicine. Parkinson's – divergent causes, convergent mechanisms. Science 2004;304:1120-2
  • Mogi M, Kondo T, Mizuno Y, Nagatsu T. p53 protein, interferon-gamma, and NF-kappaB levels are elevated in the parkinsonian brain. Neurosci Lett 2007;414:94-7
  • Resch U, Tatzber F, Budinsky A, Sinzinger H. Reduction of oxidative stress and modulation of autoantibodies against modified low-density lipoprotein after rosuvastatin therapy. Br J Clin Pharmacol 2006:61:262-74
  • Yoshino G, Hirano T, Kazumi T, et al. Fluvastatin increases LDL-particle size and reduces oxidative stress in patients with hyperlipidemia. J Atheroscler Thromb 2003;10:343-7
  • Davignon J, Jacob RF, Mason RP. The antioxidant effects of statins. Coron Artery Dis 2004;15:251-8
  • Devaraj S, Chan E, Jialal I. Direct demonstration of an antiinflammatory effect of simvastatin in subjects with the metabolic syndrome. J Clin Endocrinol Metab 2006;91:4489-96
  • Selley ML. Simvastatin prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced striatal dopamine depletion and protein tyrosine nitration in mice. Brain Res 2005;1037:1-6
  • Wang Q, Wang PH, McLachlan C, Wong PT. Simvastatin reverses the downregulation of dopamine D1 and D2 receptor expression in the prefrontal cortex of 6-hydroxydopamine-induced Parkinsonian rats. Brain Res 2005;1045:229-33
  • Wang Q, Tang XN, Wang L, et al. Effects of high dose of simvastatin on levels of dopamine and its reuptake in prefrontal cortex and striatum among SD rats. Neurosci Lett 2006;408:189-93
  • Obata T, Yamanaka Y. Protective effect of fluvastatin, a new inhibitor of 3-hydroxy- 3-methylglutaryl coenzyme A reductase, on MPP(+)-induced hydroxyl radical in the rat striatum. Brain Res 2000;860:166-9
  • Ernster L, Dallner G. Biochemical, physiological and medical aspects of ubiquinone function. Biochim Biophys Acta 1995;1271:195-204
  • Hargreaves IP, Duncan AJ, Heales SJ, Land JM. The effect of HMG-CoA reductase inhibitors on Coenzyme Q10. Drug Saf 2005;28:659-76
  • Shults CW, Oakes D, Kieburtz K, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 2002;59:1541-50
  • Müller T, Buttner T, Gholipour AF, Kuhn W. Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson's disease. Neurosci Lett 2003;341:201-4
  • Lieberman A, Lyons K, Levine J, Myerburg R. Statins, cholesterol, Co-enzyme Q10, and Parkinson's disease. Parkinsonism Relat Disord 2005;11:81-4
  • Somayajulu M, McCarthy S, Hung M, et al. Role of mitochondria in neuronal cell death induced by oxidative stress; neuroprotection by coenzyme Q10. Neurobiol Dis 2005;18:618-27
  • Storch A, Jost WH, Vieregge P, et al. Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease. Arch Neurol 2007;64:938-44
  • Folkers K, Langsjoen P, Willis R, et al. Lovastatin decreases coenzyme Q levels in humans. Proc Natl Acad Sci USA 1990;87:8931-4
  • Ghirlanda G, Oradei A, Manto A, et al. Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study. J Clin Pharmacol 1993;33:226-9
  • Laaksonen R, Ojala JP, Tikkanen MJ, Himberg JJ. Serum ubiquinone concentrations after short- and long-term treatment with HMG-CoA reductase inhibitors. Eur J Clin Pharmacol 1994;46:313-7
  • Mortensen SA, Leth A, Agner E, Rohde M. Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors. Mol Aspects Med 1997;18(Suppl):S137-44
  • Kaikkonen J, Nyyssönen K, Tuomainen TP, et al. Determinants of plasma coenzyme Q10 in humans. FEBS Lett 1999;443:163-6
  • Rundek T, Naini A, Sacco R, et al. Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke. Arch Neurol 2004;61:889-92
  • Müller T, Kuhn W, Pohlau D, Przuntek H. Parkinsonism unmasked by lovastatin. Ann Neurol 1995;37:685-6
  • Müller T. Statin-induced Parkinson-syndrome. Letter to the editor regarding the article of J. Finsterer in “Der Nervenarzt” (2003) 74:115-122 Statininduziertes Parkinson-Syndrom. Leserbrief zum Beitrag von J. Finsterer in “Der Nervenarzt” (2003) 74:115-122. Nervenarzt 2003;74:726-7
  • Duits N, Bos FM. Depressive symptoms and cholesterol-lowering drugs. Lancet 1993;341:114
  • Tatley M, Savage R. Psychiatric adverse reactions with statins, fibrates and ezetimibe: implications for the use of lipid-lowering agents. Drug Saf 2007;30:195-201
  • Sinzinger H, Mayr F, Schmid P, et al. Sleep disturbance and appetite loss after lovastatin. Lancet 1994;343:973
  • Gregoor PJ. Atorvastatin may cause nightmares. BMJ 2006;332:950
  • Kiortsis DN, Filippatos TD, Mikhailidis DP, et al. Statin-associated adverse effects beyond muscle and liver toxicity. Atherosclerosis 2007;195:7-16
  • Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9
  • Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7
  • Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with avarage cholesterol levels. N Engl J Med 1996;335:1001-9
  • The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57
  • Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA 1998;279:1615-22
  • Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22
  • Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96
  • The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care. JAMA 2002;288:2998-3007
  • Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-30
  • de Lau LM, Koudstaal PJ, Hofman A, Breteler MM. Serum cholesterol levels and the risk of Parkinson's disease. Am J Epidemiol 2006;164:998-1002
  • Huang X, Chen H, Miller WC, et al. Lower low-density lipoprotein cholesterol levels are associated with Parkinson's disease. Mov Disord 2007;22:377-81
  • de Lau LM, Stricker BH, Breteler MM. Serum cholesterol, use of lipid-lowering drugs, and risk of Parkinson disease. Mov Disord 2007;22:1985-7
  • Becker C, Jick SS, Meier CR. Use of statins and the risk of Parkinson's disease: a retrospective case-control study in the UK. Drug Saf 2008;31:399-407
  • Samii A, Carleton BC, Etminan M. Statin use and the risk of Parkinson disease: a nested case control study. J Clin Neurosci 2008;15:1272-3
  • Wahner AD, Bronstein JM, Bordelon YM, Ritz B. Statin use and the risk of Parkinson disease. Neurology 2008;70:1418-22
  • Wolozin B, Wang SW, Li NC, et al. Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Med 2007;5:20
  • Simon KC, Chen H, Schwarzschild MA, Ascherio A. Hypertension, hypercholesterolemia, diabetes, and the risk of Parkinson disease. Neurology 2007;69:1688-95
  • Frigerio R, Elbaz A, Sanft KR, et al. Education and occupations preceding Parkinson disease: a population-based case-control study. Neurology 2005;65:1575-83
  • Ritz B, Ascherio A, Checkoway H, et al. Pooled analysis of tobacco use and risk of Parkinson disease. Arch Neurol 2007;64:990-7
  • Elbaz A, Moisan F. Update in the epidemiology of Parkinson's disease. Curr Opin Neurol 2008;21:454-60
  • Litvan I, Bhatia KP, Burn DJ, et al. Movement disorders society scientific issues committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord 2003;18:467-86
  • Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114:2283-301
  • Gerlach M, Hendrich A, Hueber R, et al. Early detection of Parkinson's disease: unmet needs. Neurodegener Dis 2008;5:137-9
  • Michell AW, Lewis SJG, Foltynie T, Barker RA. Biomarkers and Parkinson's disease. Brain 2004;127:1693-705
  • Huang X, Abbott RD, Petrovitch H, et al. Low LDL cholesterol and increased risk of Parkinson's disease: prospective results from Honolulu-Asia Aging Study. Mov Disord 2008;23:1013-8
  • Hu G, Antikainen R, Jousilahti P, et al. Total cholesterol and the risk of Parkinson disease. Neurology 2008;70:1972-9
  • Stepien K, Tomaszewski M, Czuczwar SJ. Neuroprotective properties of statins. Pharmacol Rep 2005;57:561-9
  • Reiss AB, Wirkowski E. Role of HMG-CoA reductase inhibitors in neurological disorders. Drugs 2007;67:2111-20
  • Schapira A, Olanow C. Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions. JAMA 2004;291:358-64
  • Cucchiara B, Kasner SE. Use of statins in CNS disorders. J Neurol Sci 2001;187:81-9
  • Orr JD. Statins in the spectrum of neurologic disease. Curr Atheroscler Rep 2008;10:11-8
  • Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211
  • Schmidt R, Schmidt H, Curb JD, et al. Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study. Ann Neurol 2002;52:168-74
  • Levesque LE, Delaney JA, Etminan M, Suissa S. Pharmacologic interventions for the prevention of Alzheimers's disease: an example of reverse protopathic bias [abstract no. 65]. 22nd International Conference on Pharmacoepidemiology & Therapeutic Risk Management; 2006 Aug 24-27; Lisbon. Pharmacoepidemiol Drug Saf 2006;15:S31
  • Perron L, Bairati I, Moore L, Meyer F. Dosage, duration and timing of nonsteroidal antiinflammatory drug use and risk of prostate cancer. Int J Cancer 2003;106:409-15
  • Tamim H, Monfared AA, Lelorier J. Application of lag-time into exposure definitions to control for protopathic bias. Pharmacoepidemiol Drug Saf 2007;16:250-8
  • Marras C, Lang A. Invited article: Changing concepts in Parkinson disease. Neurology 2008;70:1996-2003
  • Weiner WJ. There is no Parkinson disease. Arch Neurol 2008;65:705-8

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.